A Randomized, Placebo-Controlled, Double-Blind Phase 2b Study of Raltitrexed (Tomudex) and ZD1839 (Iressa) Versus Raltitrexed Alone as Second Line Chemotherapy in Subjects With Colorectal Carcinoma

Trial Profile

A Randomized, Placebo-Controlled, Double-Blind Phase 2b Study of Raltitrexed (Tomudex) and ZD1839 (Iressa) Versus Raltitrexed Alone as Second Line Chemotherapy in Subjects With Colorectal Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2010

At a glance

  • Drugs Gefitinib; Raltitrexed
  • Indications Colorectal cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 06 Mar 2010 Results published in Investigational New Drugs.
    • 06 Mar 2010 Primary endpoint 'Progression free survival duration' has not been met according to results published in Investigational New Drugs.
    • 05 Jun 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top